GlassScriptPhysician profile
Lawrence Michael Bruner
NPI 1083104350
$1,760.77
in general payments reported to CMS, 2019-2025
27 companies · $20.56 in 2025
The $20.56 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $168 · 2022: $322 · 2023: $877 · 2024: $373 · 2025: $20.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,269.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $406.84 | 2021-2024 | |
| Novo Nordisk INC | $393.40 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $152.32 | 2021-2024 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $132.97 | 2023-2024 | Mounjaro, Reyvow, Emgality |
| Dexcom, INC. | $107.18 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $95.27 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $48.36 | 2022-2024 | Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $46.70 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $42.98 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $30.48 | 2021 | |
| Esperion Therapeutics, INC. | $25.26 | 2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $22.73 | 2023 | Rexulti |
| Amneal Pharmaceuticals LLC | $20.84 | 2023 | Unithroid |
| Scilex Pharmaceuticals INC. | $20.77 | 2023 | Ztlido |
| Exact Sciences Corporation | $20.60 | 2023 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $20.58 | 2024 | Tymlos |
| Axsome Therapeutics, INC. | $20.06 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $19.37 | 2023 | Trelegy Ellipta |
| Horizon Therapeutics Plc | $18.40 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.75 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.11 | 2023 | |
| Impel Pharmaceuticals INC. | $15.20 | 2022 | |
| Mylan Pharmaceuticals INC. | $14.97 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.46 | 2022 | |
| Astellas Pharma US INC | $13.38 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Bruner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.